Vanguard Portfolio Management
BEAM icon

Vanguard Portfolio Management’s Beam Therapeutics BEAM Stock Holding History

Vanguard Portfolio Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$169M Buy
4,921,259
+350,462
+8% +$10.6M 0.01% 1297
2026
Q1 		$109M Buy
+4,570,797
New +$127M 0.01% 1416

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management's BEAM Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Beam Therapeutics (BEAM) stake by 7.7% in Q2 2026, buying an estimated $10.6M and bringing the position to 4,921,259 shares worth $169M. The position accounts for 0.01% of the portfolio, ranked #1297.

Vanguard Portfolio Management first reported a position in BEAM in Q1 2026 and has held it in 2 quarters since. 274 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Vanguard Portfolio Management held 4,921,259 shares of Beam Therapeutics worth $169M as of Q2 2026.
  • Vanguard Portfolio Management bought 350,462 Beam Therapeutics shares in Q2 2026, an estimated $10.6M.
  • Beam Therapeutics made up 0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #1297 holding.
  • Vanguard Portfolio Management first reported a position in Beam Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 274 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.